Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 2/20 | 0.53 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.42 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.41 |
| ▸ | CDC7 | O00311 | 2/20 | 0.40 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.40 |
| ▸ | CHUK | O15111 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.38 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.36 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28292066 | 0.98 | HPGDS (0.51) | HPGDSCYP11B2CYP11B1CYP17A1CYP19A1 | |
| SCHEMBL5259772 | 0.85 | HPGDS (0.49) | HPGDSCYP11B2CYP11B1CYP17A1CYP19A1 | |
| Isoquinoline SCHEMBL27659278 | 0.84 | PDGFRB (0.47) | HPGDSCYP11B2CYP11B1CYP17A1NCOA3 | |
| SCHEMBL27893482 | 0.84 | HPGDS (0.47) | HPGDSCYP11B2CYP11B1CYP17A1CYP19A1 | |
| SCHEMBL2012088 | 0.81 | HPGDS (0.36) | HPGDSNCOA3HTTMAP4K4PDGFRB | |
| Water SCHEMBL27871202 | 0.77 | ALDH1A1 (0.57) | HPGDSPDGFRBPDGFRA | |
| SCHEMBL29788946 | 0.77 | ALDH1A1 (0.57) | HPGDSPDGFRBPDGFRA | |
| SCHEMBL63442 | 0.77 | ALDH1A1 (0.57) | HPGDSPDGFRBPDGFRA | |
| Methane SCHEMBL28479303 | 0.76 | ALDH1A1 (0.56) | HPGDSPDGFRBPDGFRA | |
| Hydrochloric Acid SCHEMBL28189040 | 0.76 | ALDH1A1 (0.56) | HPGDSPDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2696682-A2 | MIF INHIBITORS AND THEIR USES | Innovimmune Biotherapeutics, Inc. (US) | 2014-02-19 | — | — | EP | claimed |
| WO-2012142498-A2 | MIF INHIBITORS AND THEIR USES | INNOVIMMUNE BIOTHERAPEUTICS, INC. (US) | 2012-10-18 | — | — | WO | claimed |
| WO-2023061294-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 再鼎医药(上海)有限公司 | 2023-04-20 | — | — | WO | disclosed |
| CN-115583946-A | Heterocyclic compounds and their use as CDK inhibitors | 赛诺哈勃药业（成都）有限公司 | 2023-01-10 | — | — | CN | disclosed |
| CN-111471059-B | PDE9 inhibitors and uses thereof | 药捷安康(南京)科技股份有限公司 | 2022-12-02 | — | — | CN | disclosed |
| US-20220313700-A1 | METHODS FOR TREATING MAP3K8 POSITIVE CANCERS | CELL RESPONSE, INC. | 2022-10-06 | — | — | US | disclosed |
| CN-109575016-A | PDE9 inhibitors and uses thereof | 南京药捷安康生物科技有限公司 | 2019-04-05 | — | — | CN | disclosed |
| EP-2603218-B1 | QUINOLYL AMINES AS KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2016-03-02 | — | — | EP | disclosed |
| WO-2014059185-A1 | AMINO - DIHYDROTHIAZINE AND AMINO - DIOXIDO DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE ANTAGONISTS AND METHODS OF USE | AMGEN INC. (US) | 2014-04-17 | — | — | WO | disclosed |
| EP-2696682-A2 | MIF INHIBITORS AND THEIR USES | Innovimmune Biotherapeutics, Inc. (US) | 2014-02-19 | — | — | EP | disclosed |
| WO-2012142498-A2 | MIF INHIBITORS AND THEIR USES | INNOVIMMUNE BIOTHERAPEUTICS, INC. (US) | 2012-10-18 | — | — | WO | disclosed |
| US-6689772-B1 | ANTINEOPLASTIC AGENTS; OSTEOPOROSIS; POLYCYSTIC KIDNEY DISEASE; ANTIVIRAL AGENTS | WYETH | 2004-02-10 | — | — | US | disclosed |
| US-6689772-B1 | ANTINEOPLASTIC AGENTS; OSTEOPOROSIS; POLYCYSTIC KIDNEY DISEASE; ANTIVIRAL AGENTS | WYETH | 2004-02-10 | — | — | US | disclosed |
| CN-1419545-A | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors | WYETH CORP (US) | 2003-05-21 | — | — | CN | disclosed |
| US-6521618-B2 | Antineoplastic agents, agents for treatment of osteoporosis and polycystic kidney disease | WYETH | 2003-02-18 | — | — | US | disclosed |
| US-6521618-B2 | Antineoplastic agents, agents for treatment of osteoporosis and polycystic kidney disease | WYETH | 2003-02-18 | — | — | US | disclosed |
| EP-1268431-A1 | 3-CYANOQUINOLINES,3-CYANO-1,6-NAPHTHYRIDINES, AND 3-CYANO-1,7-NAPHTHYRIDINES AS PROTEIN KINASE INHIBITORS | Wyeth (US) | 2003-01-02 | — | — | EP | disclosed |
| US-20020026052-A1 | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-02-28 | — | — | US | disclosed |
| US-20020026052-A1 | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-02-28 | — | — | US | disclosed |
| WO-2001072711-A1 | 3-CYANOQUINOLINES,3-CYANO-1,6-NAPHTHYRIDINES, AND 3-CYANO-1,7-NAPHTHYRIDINES AS PROTEIN KINASE INHIBITORS | WYETH (US) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220313700-A1 | METHODS FOR TREATING MAP3K8 POSITIVE CANCERS | MAP3K8, MAP2K7, DDIT3 | HPGDS 2998/4885CYP11B2 3696/4885CYP11B1 3653/4885 |
| US-20020026052-A1 | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors | PKD1, PKD2, CSNK1A1 | HPGDS 2403/4885CYP11B2 3302/4885CYP11B1 2866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.